1.Effect of Low Dose 5-Fluorouracil and Cisplatin Intra-arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma with Decompensated Cirrhosis.
Tae Young LIM ; Jae Youn CHEONG ; Sung Won CHO ; Sung Jun SIM ; Jong Su KIM ; Sung Jun CHOI ; Jeong Woo CHOI ; Hyeok Choon KWON ; Kee Myung LEE ; Jai Keun KIM ; Je Hwan WON ; Byung Moo YOO ; Kwang Jae LEE ; Ki Baik HAHM ; Jin Hong KIM
The Korean Journal of Hepatology 2006;12(1):65-73
BACKGROUND/AIMS: Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis. The aim of this study was to evaluate the efficacy and safety of repeated arterial infusions of low dose cisplatin and 5-fluorouracil (FU) in patients with advanced HCC with decompensated cirrhosis. METHODS: Between January 1995 and December 2003, a total of 79 decompensated cirrhotic patients having HCC and PVT were enrolled and divided into 2 groups. Group 1 (n=40) received intra-arterial infusion chemotherapy with cisplatin (10 mg for 5 days) and 5-FU (250 mg for 5 days) via an implanted chemoport every 4 weeks' and group 2 (n=39) was managed with only conservative treatment. RESULTS: The two groups were well matched with respect to the features relating to the prognosis, including age, gender and the Child- Pugh class. Although diffuse tumor involvement, main portal vein tumor thrombosis and bi-lobar involvement were more frequent in group 1, the median survival period of group 1 was significantly longer than group 2 (5 months vs. 3 months, respectively, P=0.016). Also, the 1-year survival rate of group 1 (7.5%) was higher than that of group 2 (5.1%) (P=0.016). When we analyzed the patients with the Child class B, the survival benefits of intra-arterial chemotherapy were more significant (P=0.008). CONCLUSIONS: Intra-arterial chemotherapy consisting of low dose 5-FU and cisplatin achieved favorable results for advanced HCC patients who had decompensated cirrhosis, and it showed better survival in selected patients. This therapy may be useful as a palliative treatment for HCC patients with decompensated cirrhosis.
Venous Thrombosis/complications
;
Survival Rate
;
Portal Vein
;
Palliative Care
;
Middle Aged
;
Male
;
Liver Neoplasms/complications/*drug therapy/mortality
;
Liver Cirrhosis/complications
;
*Infusions, Intra-Arterial
;
Humans
;
Fluorouracil/administration & dosage
;
Female
;
Disease-Free Survival
;
Cisplatin/administration & dosage
;
Carcinoma, Hepatocellular/complications/*drug therapy/mortality
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Aged
;
Adult
2.Clinical Outcome after Living Donor Liver Transplantation in Patients with Hepatitis C Virus-associated Cirrhosis.
Jeong Ik PARK ; Kun Moo CHOI ; Sung Gyu LEE ; Shin HWANG ; Ki Hun KIM ; Chul Soo AHN ; Deok Bog MOON ; Young Hwa CHUNG ; Yung Sang LEE ; Dong Jin SUH
The Korean Journal of Hepatology 2007;13(4):543-555
BACKGROUND AND AIMS: Hepatitis C virus (HCV)-associated cirrhosis is an increasingly frequent indication for liver transplantation (LT). However, HCV recurrence is universal and this immediately occurs following LT, which endangers both the graft and patient survival. We investigated the frequency of posttransplant recurrence of HCV infection and the patient-graft survival, and we analyzed the responses to ribavirin and interferon therapy in the patients with recurrent HCV infection after living donor liver transplantation (LDLT). METHODS: We retrospectively reviewed the clinical outcomes of 39 HCV-associated cirrhosis patients who underwent LDLT at Asan Medical Center between August 1992 and June 2006. In this study, the diagnosis of recurrent HCV was made on the basis of increased transaminases and serum HCV RNA levels greater than 10 million IU/mL because protocol liver biopsy was not performed. RESULTS: HCV recurrence was seen in 26 of the 39 LDLT patients (66.7%). 86.7% of recurrence occurred within the first postoperative year. Antiviral treatment was used for all patients with recurrence of HCV. None of the 10 patients receiving ribavirin alone and 9 of 16 patients who received combination therapy with pegylated interferon alpha-2a plus ribavirin became HCV RNA negative and they remained persistently negative during the median follow-up of 24.9 months. Our data indicates that there is no significant factor influencing HCV recurrence except for the recipient's age. The 2-year patient survival for the HCV patients with HCC and those patients without HCC were 81.2% and 81.3%, respectively (P=0.85) and the 2-year graft survival rates were 81.2% and 68.2%, respectively (P=0.29). No patient died from HCV recurrence during the follow-up period. CONCLUSIONS: Combination therapy with ribavirin and interferon appears to improve the outcome of recurrent HCV infected patients after LDLT.
Adult
;
Aged
;
Antiviral Agents/therapeutic use
;
Combined Modality Therapy
;
Female
;
Graft Survival
;
Hepacivirus/drug effects/isolation & purification
;
Hepatitis C, Chronic/complications/diagnosis/*drug therapy
;
Humans
;
Interferon Alfa-2a/therapeutic use
;
Liver Cirrhosis/mortality/*surgery/*virology
;
Liver Neoplasms/mortality
;
*Liver Transplantation
;
Living Donors
;
Male
;
Middle Aged
;
Polyethylene Glycols/therapeutic use
;
Recurrence
;
Retrospective Studies
;
Ribavirin/therapeutic use
;
Severity of Illness Index
;
Treatment Outcome
3.Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis.
Hyun Young WOO ; Jun Mo YOUN ; Si Hyun BAE ; Jeong Won JANG ; Jung Hoon CHA ; Hye Lim KIM ; Ho Jong CHUN ; Byung Gil CHOI ; Jong Young CHOI ; Seoung Kew YOON
The Korean Journal of Hepatology 2012;18(1):32-40
BACKGROUND/AIMS: Low-dose metronomic chemotherapy involves the frequent administration of comparatively low doses of cytotoxic agents with no extended breaks, and it may be as efficient as and less toxic than the conventional maximum tolerated dose therapy. This study evaluated the feasibility and therapeutic efficacy of metronomic chemotherapy in patients with advanced hepatocellular carcinoma (HCC) with major portal vein thrombosis (PVT). METHODS: Thirty consecutive HCC patients with major PVT with or without extrahepatic metastasis were prospectively allocated to metronomic chemotherapy consisting of epirubicin being infused through the correct hepatic artery at a dose of 30 mg/body surface area (BSA) every 4 weeks, and cisplatin (15 mg/BSA) and 5-fluorouracil (50 mg/BSA) every week for 3 weeks, with intervening 1 week breaks. The treatment response was assessed using response evaluation criteria in solid tumors (RECIST). RESULTS: In total, 116 cycles of metronomic chemotherapy were administered to the 30 patients, with a median of 3 cycles given to individual patients (range, 1-15 cycles). Six patients (20.0%) achieved a partial response and six patients (20.0%) had stable disease. The median time to disease progression and overall survival were 63 days (range, 26-631 days) and 162 days (95% confidence interval; range, 62-262 days), respectively. Overall survival was significantly associated with baseline alpha-fetoprotein level (P=0.001) and tumor response (P=0.005). The baseline alpha-fetoprotein level was significantly associated with the disease control rate (P=0.007). Adverse events were tolerable and managed successfully with conservative treatment. CONCLUSIONS: Metronomic chemotherapy may be a safe and useful palliative treatment in HCC patients with major PVT.
Administration, Metronomic
;
Adult
;
Aged
;
Antineoplastic Agents/administration & dosage
;
Carcinoma, Hepatocellular/complications/*drug therapy/mortality
;
Cisplatin/administration & dosage
;
Epirubicin/administration & dosage
;
Female
;
Fluorouracil/administration & dosage
;
Humans
;
Kaplan-Meier Estimate
;
Liver Neoplasms/complications/*drug therapy/mortality
;
Male
;
Middle Aged
;
*Portal Vein
;
Prognosis
;
Tomography, X-Ray Computed
;
Venous Thrombosis/complications/*diagnosis
;
alpha-Fetoproteins/analysis
4.Is there any vindication for low dose nonselective beta-blocker medication in patients with liver cirrhosis?.
Tae Wan KIM ; Hong Joo KIM ; Chang Uk CHON ; Hyun Sun WON ; Jung Ho PARK ; Dong Il PARK ; Yong Kyun CHO ; Chong Il SOHN ; Woo Kyu JEON ; Byung Ik KIM
Clinical and Molecular Hepatology 2012;18(2):203-212
BACKGROUND/AIMS: Nonselective beta-blockers (NSBBs), such as propranolol, reportedly exert a pleiotropic effect in liver cirrhosis. A previous report suggested that survival was higher in patients receiving adjusted doses of NSBBs than in ligation patients. This study investigated whether low-dose NSBB medication has beneficial effects in patients with liver cirrhosis, especially in terms of overall survival. METHODS: We retrospectively studied 273 cirrhotic patients (199 males; age 53.6+/-10.2 years, mean+/-SD) who visited our institution between March 2003 and December 2007; follow-up data were collected until June 2011. Among them, 138 patients were given a low-dose NSBB (BB group: propranolol, 20-60 mg/day), and the remaining 135 patients were not given an NSBB (NBB group). Both groups were stratified randomly according to Child-Turcotte-Pugh (CTP) classification and age. RESULTS: The causes of liver cirrhosis were alcohol (n=109, 39.9%), hepatitis B virus (n=125, 45.8%), hepatitis C virus (n=20, 7.3%), and cryptogenic (n=19, 7.0%). The CTP classes were distributed as follows: A, n=116, 42.5%; B, n=126, 46.2%; and C, n=31, 11.4%. Neither the overall survival (P=0.133) nor the hepatocellular carcinoma (HCC)-free survival (P=0.910) differed significantly between the BB and NBB groups [probability of overall survival at 4 years: 75.1% (95% CI=67.7-82.5%) and 81.2% (95% CI=74.4-88.0%), respectively; P=0.236]. In addition, the delta CTP score did not differ significantly between the two groups. CONCLUSIONS: Use of low-dose NSBB medication in patients with liver cirrhosis is not indicated in terms of overall and HCC-free survival.
Adrenergic beta-Antagonists/*therapeutic use
;
Adult
;
Aged
;
Alcohol Drinking
;
Carcinoma, Hepatocellular/complications/diagnosis
;
Female
;
Follow-Up Studies
;
Humans
;
Kaplan-Meier Estimate
;
Kidney Failure, Chronic/complications/diagnosis
;
Liver Cirrhosis/complications/*drug therapy/mortality
;
Liver Neoplasms/complications/diagnosis
;
Male
;
Middle Aged
;
Predictive Value of Tests
;
Proportional Hazards Models
;
Propranolol/*therapeutic use
;
Retrospective Studies
;
Severity of Illness Index
5.Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitis.
Pei Chuan TSUNG ; Soo Hyung RYU ; In Hye CHA ; Hee Won CHO ; Jin Nam KIM ; You Sun KIM ; Jeong Seop MOON
Clinical and Molecular Hepatology 2013;19(2):131-139
BACKGROUND/AIMS: Spontaneous bacterial peritonitis (SBP) has been known to greatly influence the survival rate of patients with liver cirrhosis. However, the factors that affect the survival rate in patients with SBP need to be clarified. METHODS: This study enrolled 95 liver cirrhosis patients diagnosed with SBP. The laboratory findings of their serum and ascitic fluid were examined and the characteristics of the isolated microorganisms in their peritoneal fluid were analyzed. RESULTS: The proportion of patients with culture-positive SBP was 41.1%, and 47 microorganisms were isolated from the ascitic fluid. The proportions of cultured bacteria that were Gram negative and Gram positive were 57.4% and 40.4%, respectively. The proportions of Escherichia coli, Klebsiella species, and Streptococcus species were 25.5%, 19.1%, and 19.1%, respectively. Enterococcus species represented 12.8% of the microorganisms cultured. The overall survival rates at 6, 12, and 24 months were 44.5%, 37.4%, and 32.2%, respectively. There was no relationship between the bacterial factors and the survival rate in SBP. Multivariate analysis revealed that the presence of hepatocellular carcinoma (HCC; P=0.001), higher serum bilirubin levels (> or =3 mg/dL, P=0.002), a prolonged serum prothrombin time (i.e., international normalized ratio >2.3, P<0.001), renal dysfunction (creatinine >1.3 mg/dL, P<0.001), and lower glucose levels in the ascitic fluid (<50 mg/dL, P<0.001) were independent predictive factors of overall survival rate. CONCLUSIONS: HCC, higher serum bilirubin levels, a prolonged serum prothrombin time, renal dysfunction, and lower ascitic glucose levels are associated with higher mortality rates in cirrhotic patients with SBP.
Adult
;
Aged
;
Anti-Bacterial Agents/therapeutic use
;
Ascitic Fluid/metabolism/microbiology
;
Bilirubin/blood
;
Carcinoma, Hepatocellular/complications/diagnosis
;
Creatinine/blood
;
Female
;
Glucose/analysis
;
Gram-Negative Bacteria/isolation & purification
;
Gram-Positive Bacteria/isolation & purification
;
Humans
;
Liver Cirrhosis/complications/*mortality
;
Liver Neoplasms/complications/diagnosis
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Odds Ratio
;
Peritonitis/complications/*diagnosis/drug therapy
;
Prognosis
;
Prothrombin Time
;
Survival Rate
6.A Comparative Analysis of the Preoperative Chemoradiation Versus Radiation only for Mid and Lower Rectal Cancer.
Je Ryong KIM ; Jae Sung KIM ; Wan Hee YOON
Journal of the Korean Society of Coloproctology 1998;14(3):349-358
This study was designed to evaluate the worth of preoperative chemoradiation therapy in the management of locally advanced rectal cancer. Between march 1993 and January 1997, 64 patients with adenocarcinoma of the rectum were treated with preoperative irradiation followed by operation by one surgeon at department of surgery, Chungnam national university hospital. Cancers were treated with high-dose radiation (45 to 54 Gy) with (group 2) or without (group 1) chemotherapy Preoperatively 64 Patients were analysed prospectively, of these, 15 cases were preoperative radiotherapy alone arm and 49 cases were preoperative radiotherapy plus chemotherapy arm. The average age of the patients were 56 years (range 38~67) in group 1 and 57 years (range 27~80) in group 2. Male to female ratio was 8 : 7 in group 1 and 30 : 19 in group 2. Most clinical stage of the primary tumor mass were 73 (80% in Group 1,96% in group 2), being palpated slightly fixed (40% in group 1, 43% in group 2) or fixed (13.3% in group 1, 24.5% in group 2). As to distance of tumor from anal verge, most patients ranged from 4 to 8 cm (53% in group 1, 63.3% in Group 2). Chemotherapy consisted of 2 cycles of 5-fluorouracil (500 mg/m2/day for S days) delivered as a continuous infusion or bolus therapy and low-dose leukovorin (20 mg/m2/day for 5 days). After six weeks resting period of radiation, definitive surgical approach was performed. Overall treatment related toxicity rate was similar in both group except erythema on perineal skin, which was more frequent in group 2 than in group 1. Most frequent postoperative complication was intestinal obstruction (7.8%) followed by wound infection (6.3%), but there was no significant difference between two groups. There was one case of postoperative mortality in group 2 patients at 44 days after operation due to pneumonia and sepsis combined with liver cirrhosis. Tumor depth was downstaged in 38.5% of group 1 and 70% of group 2 patients on preoperative CT staging, and nodal downstaging was more effective on the respect of postoperative pathological report. Overall recurrence rate was 38.5% in group 1 and 20.5% in group 2. Of these, failure occured first as a distant metastasis more frequently than as a local recurrence in both group. These data do suggest that the preoperative chemotherapy and radiotherapy used are as safe as preoperative radiotherapy alone. Futhermore, tumor and lymph node downstaging are more effective in combined arm. Preoperative chemotherapy will more promising in prevention of distant metastasis when treated in the period of least metastatic tumor burden. Whether combined arm will have greater or lesser survival awaits the completion of this relevant study.
Adenocarcinoma
;
Arm
;
Chungcheongnam-do
;
Drug Therapy
;
Erythema
;
Female
;
Fluorouracil
;
Humans
;
Intestinal Obstruction
;
Leucovorin
;
Liver Cirrhosis
;
Lymph Nodes
;
Male
;
Mortality
;
Neoplasm Metastasis
;
Pneumonia
;
Postoperative Complications
;
Prospective Studies
;
Radiotherapy
;
Rectal Neoplasms*
;
Rectum
;
Recurrence
;
Sepsis
;
Skin
;
Tumor Burden
;
Wound Infection
7.Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience.
Sang Seok LEE ; Hyun Sung SHIN ; Hyung Joon KIM ; Su Jin LEE ; Hyun Suk LEE ; Kyung Hee HYUN ; Yong Hyun KIM ; Byoung Woon KWON ; Jin Hyung HAN ; Hoon CHOI ; Bae Hwan KIM ; Joon Hyuk LEE ; Ha Yan KANG ; Hyun Deok SHIN ; Il Han SONG
The Korean Journal of Hepatology 2012;18(1):48-55
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC), which is the third most common cancer in Korea, has a very poor prognosis. However, only a few studies have performed a comprehensive survival-related analysis in all patients who were consecutively diagnosed and treated over a given period of time. The aim of this study was to determine the 5-year survival rate and its prognostic factors among HCC patients. METHODS: In total, 257 patients who were consecutively diagnosed with HCC between January 2000 and December 2003 were followed until death or until December 2008. We analyzed their survival outcomes according to their clinical characteristics, tumor staging, and treatment modalities, and determined the independent prognostic factors affecting survival. RESULTS: The patients were aged 59+/-10 years (mean+/-SD). During the follow-up period, 223 patients (86.8%) died and the overall median survival was 10.8 months; the 1-, 3-, and 5-year survival rates were 44.4%, 21.0%, and 12.1%, respectively. The outcomes in patients with tumor node metastasis (TNM) stage I or II and Child-Pugh class A or B were significantly better with surgical resection than with other treatment modalities (P<0.01). Patients who underwent supplementary transcatheter arterial chemoembolization as a second-line treatment after surgical resection had better outcomes than those who underwent surgical resection alone (P=0.02). Initial symptoms, Child-Pugh class, serum alpha-fetoprotein, tumor size, portal vein thrombosis, and TNM stage were found to be independent prognostic factors for survival among HCC patients. CONCLUSIONS: This retrospective cohort study elucidated survival outcomes and prognostic factors affecting survival in HCC patients at a single center.
Aged
;
Antineoplastic Agents/therapeutic use
;
Carcinoma, Hepatocellular/drug therapy/*mortality/surgery
;
Catheter Ablation
;
Cohort Studies
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Liver Neoplasms/drug therapy/*mortality/surgery
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Portal Vein
;
Prognosis
;
Retrospective Studies
;
Severity of Illness Index
;
Survival Rate
;
Venous Thrombosis/complications
;
alpha-Fetoproteins/analysis
8.Role of Craniofacial Resection for Malignant Tumors Involving the Anterior Skull Base: Surgical Experience in a Single Institution.
You Sub KIM ; Kyung Sub MOON ; Gun Woo KIM ; Sang Chul LIM ; Kyung Hwa LEE ; Woo Youl JANG ; Tae Young JUNG ; In Young KIM ; Shin JUNG
Brain Tumor Research and Treatment 2015;3(2):81-88
BACKGROUND: Craniofacial resection (CFR) has been regarded as a standard treatment for various tumors involving the anterior skull base. The purpose of this study was to evaluate the results of CFR for the patients with anterior skull base malignancies in our hospital. METHODS: We retrospectively analyzed 17 patients with anterior skull base malignancies treated with CFR between 2001 and 2012. Mean follow-up duration was 41 months (range, 2-103 months). RESULTS: Intracranial involvement was found in 11 patients (65%) and orbital extension in 6 patients (35%). Classical bifrontal craniotomy was combined with endoscopic endonasal approach in 14 patients and external approach in 3 patients. Vascularized flap was used for reconstruction of the anterior fossa floor in 16 patients (94%). The most common pathological type was squamous cell carcinoma (6 patients). Gross total resection was achieved in all cases. Postoperative complications developed in 4 patients (24%) and included local wound problem and brain abscess. One patient with liver cirrhosis died from unexpected varix bleeding after the operation. Although postoperative treatment, such as radiotherapy or chemotherapy, was performed in 14 patients, local recurrence was seen in 6 patients. The mean overall survival time after the operation was 69.0 months (95% confidence interval: 47.5-90.5 months) with a 1-, 2-, and 5-year survival rate of 82.3%, 76.5%, and 64.7%, respectively. Postoperative radiotherapy was found to be the powerful prognostic factor for favorable survival. CONCLUSION: Considering the higher local control rate and acceptable complication or mortality rate, CFR with adjuvant radiotherapy is a gold standard treatment option for malignant tumors involving anterior skull base, especially with extensive intracranial involvement.
Brain Abscess
;
Carcinoma, Squamous Cell
;
Cranial Fossa, Anterior
;
Craniotomy
;
Drug Therapy
;
Follow-Up Studies
;
Hemorrhage
;
Humans
;
Intraoperative Complications
;
Liver Cirrhosis
;
Mortality
;
Orbit
;
Paranasal Sinus Neoplasms
;
Postoperative Complications
;
Radiotherapy
;
Radiotherapy, Adjuvant
;
Recurrence
;
Retrospective Studies
;
Skull Base*
;
Skull*
;
Survival Rate
;
Treatment Outcome
;
Varicose Veins
;
Wounds and Injuries